Sponsors

Diagnexia expands Exeter facility with 30 new jobs

Pathology diagnostics service provider Diagnexia UK - owned by Deciphex – recently celebrated the launch of its expanded facility at Exeter Science Park.

The Exeter expansion, which includes 30 new jobs, highlights Diagnexia’s commitment to driving innovation in digital pathology and supporting local employment. The expanded facility will bolster Diagnexia’s capacity to provide rapid, accurate, and high-quality pathology services to multiple NHS trusts across the UK and in its facilities in Toronto and Chicago.

Pictured are Sally Basker, CEO of Exeter Science Park, and Dr Donal O'Shea, CEO of Diagnexia UK opening the new offices. The event was attended by local dignitaries, healthcare professionals, and business leaders.

The Deciphex clinical platform, Diagnexia, connects hospitals and laboratories to an international network of subspeciality expert pathologists, who can provide their expertise on clinical cases, ensuring the delivery of the highest quality of patient care for NHS Trusts and healthcare services globally.

Dr Donal O'Shea, CEO of Diagnexia UK Limited, expressed his enthusiasm at the event, stating: "We are delighted to expand our presence in Exeter, a city that has consistently demonstrated its commitment to innovation and growth in the healthcare sector. Our new facility at Exeter Science Park will enable us to better serve our clients across the UK and beyond, while also providing valuable employment opportunities in the local community."

The Deciphex Exeter Accession Facility is the central hub for the digitisation and upload of all biopsies to the Diagnexia Platform. The expansion of the Exeter accession facility along with the creation of 30 new jobs this year will triple the capacity at the facility to meet growing demand for services.

Attending the event, Steve Blunden, Head of Histopathology at University Hospitals Plymouth NHS Trust acknowledged the potential impact of the expansion on the regional healthcare community. "Diagnexia's investment in Exeter and the South West is testament to the region's growing reputation as a hub for innovation and excellence in healthcare. We look forward to the opportunities this expansion will bring, both for the local economy and for improved patient care in the region."

This expansion has been supported by South West Local Enterprise Partnership through the award of the European Regional Development Fund Inward Investment Support Grant Scheme to Deciphex.

 

Latest Issues

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024

11th Digital Pathology & AI Congress: Europe

Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024

Microbiology Society Annual Conference 2025

Liverpool Arena and Convention Centre
31 March - 3 April, 2025

BSMT Annual Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025